ARA-290

InvestigationalTissue Repair ResearchRecovery & tissue repairImmune & gut
6.7

Worth trying, BioHarmony verdict

BioHarmony score 6.7 out of 10

ARA-290 (cibinetide) is an EPO-derived peptide that activates the innate repair receptor to regrow small nerve fibers without EPO's blood effects. Corneal nerve fiber area rose significantly at 4 mg per day, per Culver 2017, but it never passed Phase 2 and is grey-market only.

Read full report

What is ARA-290?

ARA-290 (cibinetide) is an 11-amino-acid peptide built from the helix-B region of erythropoietin, and it pairs real Phase 2 human trials with a narrow, niche use and a stalled development path. It activates the innate repair receptor, the EPO receptor joined to the beta-common receptor (CD131), to calm overactive innate immunity and drive small-fiber nerve repair. The clever part is what it leaves out: it skips the EPO-receptor homodimer that raises red blood cells and clotting, so you get the protective signaling of EPO without its blood risk. The headline human result is structural, with a significant rise in corneal nerve fiber area at 4 mg per day, per Culver 2017.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

How it is thought to work

Activates the innate repair receptor (EPO receptor plus CD131) without the EPO-receptor homodimer that raises red blood cells

Safety watch-outs

  • Any active or suspected cancer: do not use
  • tissue-growth-promoting agents in the EPO pathway are an unstudied risk in people.
  • New or worsening allergic-type reaction at or beyond the injection site: stop and consult a clinician.
  • Pregnancy, breastfeeding, or pediatric use: no human safety data exists, so avoid.
  • Product of unknown provenance or no certificate of analysis: the clean trial safety record was achieved with pharmaceutical-grade material…

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for ARA-290 yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (2)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalInvestigational
CompoundingEligibility not established.

ARA-290, also called cibinetide, has reached human Phase 2 research. The reviewed diabetic macular edema study reported a 12-week course as safe in that trial and called for further investigation; it did not establish an approved treatment.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.